COIOSDeep risk insights through multi-disciplinary research across the globe
people waiting at a food stand
Item new Peer-reviewed Added

Oral safiglipron lowered HbA1c as much as dapagliflozin, and more at 90 mg

In adults with type 2 diabetes, once-daily oral safiglipron lowered HbA1c at least as much as dapagliflozin, and by more at the 90 mg dose.

A trial compared once-daily oral safiglipron against dapagliflozin in adults with type 2 diabetes. Safiglipron lowered HbA1c at least as much as dapagliflozin at every dose tested, and by more at 90 mg. Weight loss was modest and similar in both arms.

Why it is interesting: An oral agent tested against a standard oral diabetes drug rather than against placebo.

Source
Nature Medicine, 5 October 2026
Type
Peer-reviewed article
Design
Randomised, double-blind, active-comparator phase 3 trial of once-daily oral safiglipron versus dapagliflozin in adults with type 2 diabetes; sample size and duration not stated in the abstract
Verdict
New finding
Driver
Obesity, diabetes and GLP-1

Other drivers in Health today